Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 7 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The earnings contribution from collaboration with SBC Medical Group gained momentum in the second half, while the expansion of transactions and other activities in the Medical Support business continued in the fourth quarter. As a result of higher sales, gross profit increased, and the company also recorded a ¥135 million tax adjustment gain following its review of the recoverability of deferred tax assets.
| Item | Details |
|---|---|
| Net Sales | ¥2,750 million → ¥2,990 million（+8.7%） |
| Operating profit | ¥560 million → ¥691 million（+23.5%） |
| Ordinary income | ¥550 million → ¥684 million（+24.4%） |
| Profit attributable to owners of the parent | ¥410 million → ¥752 million（+83.5%） |
| Net income per share | 115.57 Yen/sen → 212.07 Yen/sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 7 August 2026 |
| Previous-period results | Consolidated results for the fiscal year ended September 2025: net sales ¥1,960 million, operating profit ¥150 million, ordinary profit ¥152 million, net income attributable to owners of the parent ¥44 million, basic earnings per share ¥12.32 |
| Reason for the revision | The earnings contribution from collaboration with SBC Medical Group gained momentum in the second half, while the expansion of transactions and other activities in the Medical Support business continued in the fourth quarter. As a result of higher sales, gross profit increased, and the company also recorded a ¥135 million tax adjustment gain following its review of the recoverability of deferred tax assets. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in the Medical Support business increased due to collaboration with SBC Medical Group and the expansion of transactions, resulting in higher gross profit. In addition, following a review of the recoverability of deferred tax assets, the company recorded a ¥135 million tax adjustment gain.